Autolus Therapeutics plc (AUTL) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Autolus Therapeutics (AUTL) Q1 2026: Gross Margin Turns Positive as Center Penetration Reaches 73
  May 14, 2026
• Autolist (AUTL) Q4 2025: 92% Real-World Remission Validates $120M+ Guidance and Expansion Ambitions
  March 27, 2026
• Autoless Therapeutics (AUTL) Q3 2025: Deferred Revenue Climbs to $7.6M, Signaling Uptick in CAR T Therapy Demand
  November 12, 2025
• Autolus (AUTL) Q2 2025: 46 U.S. Centers Activated, Setting Stage for Broad OB-Cell Uptake
  August 12, 2025
• Autolus (AUTL) Q1 2025: 39 Centers Activated, Laying Foundation for U.S. CAR-T Expansion
  July 05, 2025
• Altalist Therapeutics (AUTL) Q3 2024: 30 Centers Activated for Orcatzel Launch, Reaching 60% of U.S. ALL Patients
  November 12, 2024
• Autolus (AUTL) Q2 2024: Cash Position Swells to $706M as OB-Cell Nears FDA Decision
  August 08, 2024
• Autolus Therapeutics (AUTL) Q1 2024: $600M Capital Infusion Fuels Commercial Launch and Autoimmune Pipeline Expansion
  May 17, 2024
• Autolus Therapeutics (AUTL) Q4 2023: BioNTech Alliance Adds $250M, Extending Cash Runway for OB-Cell Launch
  March 14, 2024

Browse all companies